OpenAI backs Sam Altman’s brain-computer interface startup Merge Labs

OpenAI has made a significant investment in Merge Labs, a startup focusing on brain-computer interfaces (BCIs) that is led by its CEO, Sam Altman. This move adds another dimension to the intricate network of collaborations surrounding the prominent AI firm. Emerging from stealth mode on January 15, Merge Labs positions itself as a research entity dedicated to merging biological and artificial intelligence to enhance human capabilities. This investment also intensifies Altman’s involvement in advanced technologies, setting the stage for competition with Elon Musk's Neuralink, which is also developing BCIs to help individuals with paralysis control devices through thought alone. In a statement regarding the investment, OpenAI remarked, "Advancements in interfaces pave the way for computing progress. Brain-computer interfaces represent a crucial new frontier, offering innovative methods for communication, learning, and interaction with technology." Merge Labs aims to revolutionize existing BCI approaches by significantly increasing bandwidth while reducing invasiveness. Instead of traditional implant-based techniques, the company is exploring methods that engage neurons using molecules rather than electrodes, utilizing advanced modalities like ultrasound for information transmission. The vision for Merge Labs includes creating interfaces that effectively integrate biology, technology, and AI in a manner that is safe, scalable, and accessible. The founding team comprises notable researchers, including Mikhail Shapiro, Tyson Aflalo, and Sumner Norman, alongside tech entrepreneurs such as Alex Blania and Sandro Herbig, with Altman also involved personally. OpenAI highlighted that AI will be integral to Merge's research, accelerating advancements in bioengineering, neuroscience, and device innovation while enabling AI systems to accurately interpret intentions from limited neural signals. Initially, Merge Labs will function as a research facility with aspirations to develop products aimed at restoring lost functions for patients suffering from neurological conditions, eventually extending into broader applications for human enhancement.